Shield Therapeutics reported a 41% increase in revenue to $30.4 million in the first half of 2026, boosted by a $7.9 million milestone payment from partner ASK and higher royalties. Despite this, group revenue and ACCRUFeR net revenue declined due to softer second-quarter trading and changes in Medicaid prescription rules affecting prices. The company shifted focus to commercial patients, growing that segment by 27%, with total prescriptions up 21%. Cash reserves fell to $8.3 million by June, and the company secured a new contract expanding clinic access. Shares fell 20.5% following the report, while the company remains on track for profitability in 2026.
An analyst has reiterated a Strong Buy rating on Seagate Technology, increasing the price target from $1410 to $1624 per share. The upgrade is driven by strong demand for AI data center storage, new product cycles including Mozaic and HAMR, improved ...
Seagate Technology and Nebius Group saw their common stock and convertible bonds increase during the quarter following strong earnings reports and robust revenue growth. In contrast, Eni's stock declined amid a broader energy sector selloff, despite ...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Investors are rotating out of AI infrastructure stocks such as Micron and Western Digital, which surged earlier this year due to memory shortages but have recently declined. CNBC's Jim Cramer highlights a shift toward companies with broader growth dr...
